List view / Grid view
The agreement enables the EU and European Economic Area (EEA)…
18 November 2021 | By
The agreement enables the EU and European Economic Area (EEA) countries to donate Moderna's COVID-19 vaccine to low-income countries.
Moderna will build an mRNA facility in Africa to manufacture…
Moderna will build an mRNA facility in Africa to manufacture 500 million doses of their COVID-19 vaccine and other products per year.
![Moderna COVID-19 vaccine vials [Credit: Giovanni Cancemi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1893225814-300x278.jpg)
![Moderna COVID-19 vaccine vials [Credit: Giovanni Cancemi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1893225814-e1631790550214.jpg)
New data shows that Moderna’s COVID-19 vaccine protects against variants…
New data shows that Moderna’s COVID-19 vaccine protects against variants of concern and reduces breakthrough infection risk.
![Vials labelled MODERNA COVID-19 VACCINE [Credit: Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Moderna-vaccines-300x278.jpg)
![Vials labelled MODERNA COVID-19 VACCINE [Credit: Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Moderna-vaccines-e1628853168752.jpg)
With sales of its COVID-19 vaccine accounting for $5.9 billion…
With sales of its COVID-19 vaccine accounting for $5.9 billion in revenue, Moderna reports H1 revenue 84-fold higher than in 2020.
Moderna and the Canadian government are collaborating to build an…
Moderna and the Canadian government are collaborating to build an mRNA vaccine manufacturing facility in Canada.
Moderna tops the 2021 Best Workplaces for Innovators list following…
Moderna tops the 2021 Best Workplaces for Innovators list following its "epic" COVID-19 vaccine development journey and impressive growth in 2020.
Moderna’s mRNA respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, gains…
Moderna’s mRNA respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, gains Fast Track designation in adults over 60 years old.
The Phase I/II trial will assess the safety, reactogenicity and…
The Phase I/II trial will assess the safety, reactogenicity and immunogenicity of Moderna’s mRNA-1010 seasonal flu vaccine.
Here EPR summarises the latest news from Moderna on the…
Here EPR summarises the latest news from Moderna on the licensure, supply and distribution of its mRNA COVID-19 vaccine.
New Phase II/III study data shows Moderna’s COVID-19 vaccine is…
New Phase II/III study data shows Moderna’s COVID-19 vaccine is safe and immunogenic in patients aged 12 to less than 18 years old.
The Phase II/III trial will assess the safety and efficacy…
The Phase II/III trial will assess the safety and efficacy of the COVID-19 Vaccine Moderna in children aged six months to less than 12 years.
Moderna has shipped the trial material for its mRNA-1273.351 vaccine…
Moderna has shipped the trial material for its mRNA-1273.351 vaccine candidate to the US National Institutes of Health for Phase I trials.
Results from in vitro neutralisation studies have shown that Moderna's…
Results from in vitro neutralisation studies have shown that Moderna's COVID-19 vaccine is effective against emerging strains of SARS-CoV-2.
Europe will receive an extra 80 million doses of Moderna's…
Europe will receive an extra 80 million doses of Moderna's mRNA-1273, a COVID-19 vaccine candidate, following the EC's decision.
The first participants ages 12 to less than 18 have…
The first participants ages 12 to less than 18 have been dosed in the study of mRNA-1273, Moderna's vaccine candidate against COVID-19.
